Newron Pharmaceuticals SpA / Key word(s): Miscellaneous
13-Apr-2021 / 12:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Milan, Italy – April 13, 2021 – Newron Pharmaceuticals S.p.A. (‘Newron’) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being the approval of the Company’s balance sheet as of 31 December 2020 (including related and consequent resolutions).
About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago(R)/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com
For more information
End of ad hoc announcement
|Company:||Newron Pharmaceuticals SpA|
|Via Antonio Meucci 3|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1184162|
|End of Announcement||EQS Group News Service|